Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Depreciation & Amortization (CF) (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Depreciation & Amortization (CF) readings, the most recent being $29000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 98.38% to $29000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $350000.0, a 93.58% decrease, with the full-year FY2025 number at $2.1 million, down 58.11% from a year prior.
  • Depreciation & Amortization (CF) hit $29000.0 in Q1 2026 for Atara Biotherapeutics, down from $49000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.8 million in Q1 2025 to a low of $29000.0 in Q1 2026.
  • Median Depreciation & Amortization (CF) over the past 5 years was $1.2 million (2023), compared with a mean of $1.0 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 29.04% in 2025 and later crashed 98.38% in 2026.
  • Atara Biotherapeutics' Depreciation & Amortization (CF) stood at $1.3 million in 2022, then dropped by 3.98% to $1.2 million in 2023, then fell by 8.71% to $1.1 million in 2024, then crashed by 95.55% to $49000.0 in 2025, then tumbled by 40.82% to $29000.0 in 2026.
  • The last three reported values for Depreciation & Amortization (CF) were $29000.0 (Q1 2026), $49000.0 (Q4 2025), and $36000.0 (Q3 2025) per Business Quant data.